Rapid Point Care Testing Sickle Cell Anemia Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Rapid point-of-care (PoC) testing for sickle cell anemia comprises in vitro diagnostic products that enable near-patient or bedside detection of sickle cell disease and trait within minutes, bypassing the need for conventional laboratory infrastructure. The market was valued at approximately $304.8 million in 2024 and is tracked at roughly $328.7 million in 2025, with 2026 estimates around $356-362 million. By 2030, the market is forecast to reach approximately $522.8 million, reflecting a 9.7% CAGR over the projection period, with some alternative projections extending to $735.4 million by 2033 at a 10.9% CAGR.

• •Estimated 2024 value: ~$304.8 million USD; 2025: ~$328.7 million USD; 2026: ~$356-362 million USD
• •Projected 2030 value: ~$522.8 million USD at 9.7% CAGR; some projections extend to ~$735.4 million USD by 2033
• •Products include lateral flow, immunochromatographic, and isothermal nucleic acid amplification tests

A primary growth engine is the global public health push to scale newborn screening for sickle cell disease, particularly across sub-Saharan Africa and India where the disease burden is highest and laboratory infrastructure remains limited. The shift toward decentralized diagnostic models in low- and middle-income countries, supported by multilateral health organizations and national health programs, amplifies demand for tests that do not require electricity, cold chain, or highly trained technicians. Technological improvements in lateral flow assay sensitivity, coupled with falling per-test costs, further reduce adoption barriers in both clinical and community-based screening settings.

• •Newborn screening mandates and pilot programs in high-burden regions drive repeat procurement and scale-up
• •Decentralized care models and field screening campaigns expand addressable market beyond hospital laboratories
• •Advances in assay sensitivity and cost reduction improve accessibility in low-resource settings

The market is typically segmented by product type, including immunochromatographic/lateral flow tests and molecular PoC platforms, as well as by end user (hospitals, diagnostic laboratories, blood banks, and field screening programs) and geography. North America and Europe account for the largest revenue share due to established healthcare infrastructure and early adoption of advanced diagnostics. However, the fastest growth is occurring in Africa, the Middle East, and South Asia, where high sickle cell trait prevalence, rising government screening commitments, and donor-funded public health initiatives are creating expanding demand.

• •Product segments: lateral flow/immunoassay kits and molecular PoC devices (e.g., isothermal amplification)
• •End users: hospitals and clinics, diagnostic labs, blood banks, and community screening programs
• •Africa and South Asia are the highest-growth regions driven by disease burden and screening scale-up

Who are the notable companies in the industry?

I'm unable to complete this request as specified. **Bio-Rad is not mentioned anywhere in the provided research text**, so I cannot write a factual descriptor for it drawn from that text alone, and I won't fabricate company details or market positions. The research text contains essentially one relevant market paragraph (market size, CAGR, and technology trends) and a general structural description naming **no specific companies**. The named entities in the research (Pathward, Cincinnati Metro, RapidSOS) are unrelated to sickle cell point-of-care diagnostics. To produce the rewrite you're asking for, I would need research text that actually identifies Bio-Rad and its role in this specific market. If you can provide that source material, I'll be happy to weave Bio-Rad and any other named players into the competitive landscape section using only the details found in the text.

• •Structure ranges from integrated multinational diagnostics and life sciences firms to smaller specialty PoC assay developers
• •Two core technology routes: immunoassay-based lateral flow (low cost, broad screening) and isothermal molecular amplification (higher specificity)
• •Manufacturing and R&D capacity concentrated in North America, Western Europe, and East Asia; regional partnerships growing in Africa

What are the recent trends and outlook?

Looking ahead, the market is expected to benefit from continued expansion of national sickle cell screening policies, increasing integration of PoC testing into antenatal and newborn care pathways, and ongoing innovation in multiplex and affordable molecular platforms suitable for field conditions. Regulatory harmonization across African and Asian markets through bodies such as the African Medicines Agency is likely to streamline product registration and market entry. Longer-term, the convergence of PoC diagnostics with digital health reporting tools may further accelerate adoption by enabling real-time surveillance and patient tracking in large-scale screening campaigns.

• •National screening policy adoption and antenatal care integration are expected to sustain double-digit growth through 2030
• •Regulatory harmonization efforts in target regions may lower barriers to market entry for assay manufacturers
• •Digital integration and multiplex assay development are emerging as differentiating innovation themes